The iconic rise of Viagra has consistently remained a benchmark of pharmaceutical success, yet its future within the broader industry now raises questions about long-term yields . Copycat versions are diminishing market share, prompting anxieties that supporting companies heavily reliant to Viagra's previous position could be a speculative strategy